- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Cipla and Kemwell Collaborate on Lung Disease Biosimilars
Cipla, a medicines developer and retailer, and Kemwell Biopharma, a contract manufacturer, intend to produce biosimilars for lung disorders.
Two India-based companies said they have formed a partnership to develop biosimilars for respiratory disease. Their goal is to sell these biosimilars in global markets.
Cipla, based in Mumbai, and Kemwell Biopharma, of Bengaluru, will pair their complementary strengths in product development, clinical development, regulatory filings, manufacturing, and commercialization to develop the biosimilars pipeline, they said.
“This development reinforces our strength as leaders in respiratory therapy and is in line with our aspiration of global lung leadership,” Umag Vohra, managing director and CEO of Cipla, said in a statement.
Cipla is a lung disease specialist with products on the international markets for asthma, chronic obstructive pulmonary disease, allergic rhinitis, and other conditions. The company also produces medicines across multiple other therapeutic categories, including diabetes, women’s health, and tuberculosis.
Besides India, the company has facilities in Africa and North America. The company’s plant in Durban, South Africa, was recently vandalized and looted during the political violence over the jailing of former president Jacob Zuma, but has since reopened.
Kemwell is a contract biologics development and manufacturing company. Kemwell boasts facilities designed in collaboration with German expertise and has partnered with Bayer, GlaxoSmithKline, Merck, Novartis, and Pfizer, according to its website. Kemwell has manufacturing plants in Sweden.
For companies in the developing world, it is important to reassure international clients and markets that facilities and products meet high standards.
Health Canada Approves First Omalizumab Biosimilar
December 16th 2024Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Aflibercept Biosimilar MYL-1701P Provides Equivalence in DME Therapy
November 27th 2024The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME.
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
November 26th 2024The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.
